Drugs like pembrolizumab (Keytruda) can be used in combination with chemotherapy to enhance the immune response against cancer. Radiation Therapy: Radiation therapy uses high-energy rays to target and ...

The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy, followed by adjuvant pembrolizumab demonstrated significant overall-survival improvement in patients with ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

The market is also wondering how Merck may eventually need to find a replacement for its top-selling Keytruda immunotherapy ...

For Merck, the drug that concerns investors is Keytruda. The blockbuster cancer drug faces patent expiration in 2028.

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Pietro’s Trattoria broke ground for their new restaurant in Reynolds Ranch a couple weeks ago, according to owner Pete ...

Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -- Phase 1 ...

Summit Therapeutics (NASDAQ: SMMT) is a biotech stock that few investors have heard of, but it has the makings of a winner ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...